ISTA Pharmaceuticals Highlights BEPREVE Clinical Data at the 2011 AAAAI Annual Meeting

ISTA Pharmaceuticals, Inc. ISTA, today announced additional results from the Company's BEPREVE 1.5% Phase 3 clinical studies in allergic conjunctivitis. These results were presented in poster sessions at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, CA. In a poster presentation titled "Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nonocular Composite Symptom Scores 16 Hours Following Dosing in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis," the Phase 3 studies demonstrated BEPREVE was statistically superior to placebo in reducing summed NOCS scores up to 16 hours after ophthalmic dosing. The data shows support for the clinical effectiveness of BEPREVE in reducing nonocular symptoms associated with allergic conjunctivitis.